Litcius/Paper detail

Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine

Ruth A. Karron, Nigel S. Key, Joshua M. Sharfstein

2021JAMA27 citationsDOIOpen Access PDF

Abstract

Isaac See, MD; John R. Su, MD, PhD, MPH; Allison Lale, MD, MPH; Emily Jane Woo, MD, MPH; Alice Y. Guh, MD, MPH; Tom T. Shimabukuro, MD, MPH, MBA; Michael B. Streiff, MD; Agam K. Rao, MD; Allison P. Wheeler, MD, MSCI; Suzanne F. Beavers, MD; Anna P. Durbin, MD; Kathryn Edwards, MD; Elaine Miller, RN, MPH; Theresa A. Harrington, MD, MPH&TM; Adamma Mba-Jonas, MD, MPH; Narayan Nair, MD; Duong T. Nguyen, DO; Kawsar R. Talaat, MD; Victor C. Urrutia, MD; Shannon C. Walker, MD; C. Buddy Creech, MD; Thomas A. Clark, MD, MPH; Frank DeStefano, MD, MPH; Karen R. Broder, MD

Topics & Concepts

MedicineHeparin-Induced Thrombocytopenia and ThrombosisIntramuscular injections and effectsPlatelet Disorders and Treatments
Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine | Litcius